SCHEMBL1364239

SCHEMBL1364239

CCCC(=O)N1CCC(NC(=O)c2cnc(-c3ccccc3)nc2C)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.48
CDK1 P06493 1/20 0.46
CDK4 P11802 1/20 0.46
CCND1 P24385 1/20 0.46
CDK2 P24941 1/20 0.46
CCR8 P51685 4/20 0.45
CKS1B P61024 2/20 0.45
SKP1 P63208 2/20 0.45
SKP2 Q13309 2/20 0.45
ALDH1A1 P00352 6/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 4/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TSHR P16473 1/20 0.43
LMNA P02545 1/20 0.42
THRB P10828 1/20 0.42
EPHX2 P34913 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4406616 0.87 KDM4E (0.58) ALDH1A1MEN1KMT2AL3MBTL1KDM4E
SCHEMBL14094525 0.84 DGAT1 (0.53) DGAT1CKS1BSKP1SKP2ALDH1A1
SCHEMBL1364923 0.84 DGAT1 (0.53) DGAT1CDK2CKS1BSKP1SKP2
SCHEMBL1366388 0.82 POLB (0.63) MEN1KMT2ATSHRLMNASMN1; SMN2
SCHEMBL1367559 0.82 DGAT1 (0.51) DGAT1CKS1BSKP1SKP2ALDH1A1
SCHEMBL1366822 0.79 DRD4 (0.60) DGAT1ALDH1A1L3MBTL1KDM4ETSHR
SCHEMBL1366703 0.78 DGAT1 (0.55) DGAT1SMN1; SMN2
SCHEMBL1366750 0.76 CKS1B (0.47) CKS1BSKP1SKP2ALDH1A1MEN1
SCHEMBL12141992 0.74 KMT2A (0.51) CDK2CKS1BSKP1SKP2ALDH1A1
SCHEMBL2071379 0.73 HPGDS (0.54) CCR8ALDH1A1KDM4EHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067589-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2011-11-29 US disclosed
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions BLAKE TANISHA D 2009-11-12 US disclosed
US-7582643-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2009-09-01 US disclosed
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions BLAKE TANISHA D 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions CYP11B2, CYP11B1, LTC4S DGAT1 1566/4885CDK1 2509/4885CDK4 1598/4885
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions CYP11B2, CYP11B1, LTC4S DGAT1 1566/4885CDK1 2509/4885CDK4 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.